KR20240137084A - 활성화가능한 이중특이적 항-cd47 및 항-pd-l1 단백질 및 그의 용도 - Google Patents

활성화가능한 이중특이적 항-cd47 및 항-pd-l1 단백질 및 그의 용도 Download PDF

Info

Publication number
KR20240137084A
KR20240137084A KR1020247028692A KR20247028692A KR20240137084A KR 20240137084 A KR20240137084 A KR 20240137084A KR 1020247028692 A KR1020247028692 A KR 1020247028692A KR 20247028692 A KR20247028692 A KR 20247028692A KR 20240137084 A KR20240137084 A KR 20240137084A
Authority
KR
South Korea
Prior art keywords
cancer
seq
protein
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247028692A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 제임스 조나단 핀레이
Original Assignee
센테사 파마슈티칼스 (유케이) 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 센테사 파마슈티칼스 (유케이) 리미티드 filed Critical 센테사 파마슈티칼스 (유케이) 리미티드
Publication of KR20240137084A publication Critical patent/KR20240137084A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020247028692A 2022-01-31 2023-01-31 활성화가능한 이중특이적 항-cd47 및 항-pd-l1 단백질 및 그의 용도 Pending KR20240137084A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263305003P 2022-01-31 2022-01-31
US63/305,003 2022-01-31
US202263309759P 2022-02-14 2022-02-14
US63/309,759 2022-02-14
US202263342283P 2022-05-16 2022-05-16
US63/342,283 2022-05-16
US202263348842P 2022-06-03 2022-06-03
US63/348,842 2022-06-03
PCT/EP2023/052366 WO2023144423A1 (en) 2022-01-31 2023-01-31 Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof

Publications (1)

Publication Number Publication Date
KR20240137084A true KR20240137084A (ko) 2024-09-19

Family

ID=85199086

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247028692A Pending KR20240137084A (ko) 2022-01-31 2023-01-31 활성화가능한 이중특이적 항-cd47 및 항-pd-l1 단백질 및 그의 용도

Country Status (9)

Country Link
US (1) US20250002585A1 (https=)
EP (1) EP4473012A1 (https=)
JP (1) JP2025504955A (https=)
KR (1) KR20240137084A (https=)
AU (1) AU2023210844A1 (https=)
CA (1) CA3251615A1 (https=)
IL (1) IL314395A (https=)
MX (1) MX2024009251A (https=)
WO (1) WO2023144423A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
CN111212852A (zh) 2017-08-18 2020-05-29 超人肆有限公司 结合剂
US20240124889A1 (en) * 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
GB201906685D0 (en) * 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
CN116390939A (zh) * 2020-08-04 2023-07-04 埃克塞里艾克西斯公司 多重特异性结合剂及其用途

Also Published As

Publication number Publication date
IL314395A (en) 2024-09-01
JP2025504955A (ja) 2025-02-19
US20250002585A1 (en) 2025-01-02
MX2024009251A (es) 2024-08-06
AU2023210844A1 (en) 2024-08-01
CA3251615A1 (en) 2023-08-03
EP4473012A1 (en) 2024-12-11
WO2023144423A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
TWI703159B (zh) Bcma特異性治療性抗體及其用途
JP7324749B2 (ja) Ｃｄ１２３に特異的な抗体および抗体－薬物コンジュゲートならびにその使用
KR20220008841A (ko) 인간 면역글로불린 힌지 영역인 두 개의 결합 도메인 사이의 링커 또는 이의 변이체를 포함하는 활성화 가능한 이중특이성 항체 및 이의 용도
EP3988569A1 (en) Antibodies to pd-1 and uses thereof
TW202334213A (zh) 可活化之抗ctla-4抗體及其用途
TW201708255A (zh) 抗ｏｘ４０抗體及其用途
RS66837B1 (sr) Agensi sa dvostrukim vezivanjem za pd1 i vegfr2
TW202309088A (zh) 新的穩定抗ｖｉｓｔａ抗體
TW202545564A (zh) 治療性蛋白質之醫藥組成物及使用方法
WO2024023273A1 (en) Bispecific anti-c-kit and anti-cd203c antigen-binding molecules and uses thereof
US20250109206A1 (en) Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof
KR20240111823A (ko) 항-cd47 항체 및 이의 사용 방법
US20250002585A1 (en) Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof
CN118786144A (zh) 可活化双特异性抗cd47和抗pd-l1蛋白质及其用途
WO2024218512A1 (en) Activatable bispecific anti-cd89 and anti-pd-l1 proteins and uses thereof
CN121335925A (zh) 可活化的双特异性抗cd28和抗pd-l1蛋白质及其用途
TW202602924A (zh) 抗ccr8抗體之醫藥配製物
HK40035879A (en) Bi-specific antigen-binding polypeptides
HK1246308B (en) Antibodies against ox40 and uses thereof
HK1233656B (en) Bi-specific antigen-binding polypeptides
HK1233656A1 (en) Bi-specific antigen-binding polypeptides

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000